Rocket Pharmaceuticals/RCKT

$21.20

2.61%
-
1D1W1MYTD1YMAX

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company. The Company is advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Its lentiviral (LV) vector-based gene therapies target hematologic diseases and consist of late-stage programs for Fanconi Anemia, a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. It also has two clinical stages and one pre-clinical stage in vivo adeno-associated virus (AAV) programs, including programs for Danon disease, Plakophilin-2 Arrhythmogenic Cardiomyopathy and BAG3 Dilated Cardiomyopathy.

Ticker

RCKT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Gaurav Shah

Employees

268

Headquarters

New york, United States

RCKT Metrics

BasicAdvanced
$1.9B
Market cap
-
P/E ratio
-$2.87
EPS
1.06
Beta
-
Dividend rate
$1.9B
1.06486
$32.53
$14.89
687K
10.473
4.386
4.795
-49.16%
-55.38%
-52.49%
4.299
5.04
13.4%

What the Analysts think about RCKT

Analyst Ratings

Majority rating from 15 analysts.
Buy

Price Targets

Average projection from 12 analysts.
136.23% upside
High $65.00
Low $39.00
$21.20
Current price
$50.08
Average price target

RCKT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$62M
4.03%
Profit margin
0%
NaN%

RCKT Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 3.06%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.82
-$0.75
-$0.64
-$0.66
-
Expected
-$0.79
-$0.81
-$0.79
-$0.68
-$0.72
Surprise
3.8%
-7.23%
-18.56%
-3.06%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Rocket Pharmaceuticals stock?

Rocket Pharmaceuticals (RCKT) has a market cap of $1.9B as of May 30, 2024.

What is the P/E ratio for Rocket Pharmaceuticals stock?

The price to earnings (P/E) ratio for Rocket Pharmaceuticals (RCKT) stock is 0 as of May 30, 2024.

Does Rocket Pharmaceuticals stock pay dividends?

No, Rocket Pharmaceuticals (RCKT) stock does not pay dividends to its shareholders as of May 30, 2024.

When is the next Rocket Pharmaceuticals dividend payment date?

Rocket Pharmaceuticals (RCKT) stock does not pay dividends to its shareholders.

What is the beta indicator for Rocket Pharmaceuticals?

Rocket Pharmaceuticals (RCKT) has a beta rating of 1.06. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Rocket Pharmaceuticals stock price target?

The target price for Rocket Pharmaceuticals (RCKT) stock is $50.08, which is 134.68% above the current price of $21.34. This is an average based on projections from 12 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Rocket Pharmaceuticals stock

Buy or sell Rocket Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing